2022
Association of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer
Zhan PL, Canavan ME, Ermer T, Pichert MD, Li AX, Maduka RC, Boffa DJ. Association of Insurance Status and Extent of Organ Involvement With Survival Among Patients With Stage IV Cancer. JAMA Network Open 2022, 5: e2217581. PMID: 35713907, PMCID: PMC9206181, DOI: 10.1001/jamanetworkopen.2022.17581.Peer-Reviewed Original ResearchRevisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasis
2021
The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases
Salazar MC, Canavan ME, Walters SL, Chilakamarry S, Ermer T, Blasberg JD, Yu JB, Gross CP, Boffa DJ. The Survival Advantage of Lobectomy over Wedge Resection Lessens as Health-Related Life Expectancy Decreases. JTO Clinical And Research Reports 2021, 2: 100143. PMID: 34590002, PMCID: PMC8474228, DOI: 10.1016/j.jtocrr.2021.100143.Peer-Reviewed Original ResearchStage I NSCLCWedge resectionSurveillance EpidemiologyMortality riskHigh riskSurvival advantageLife expectancyNational Cancer Institute's Surveillance EpidemiologyEnd Results-MedicareTreatment-naive patientsEarly-stage NSCLCRetrospective cohort studySuperior local controlShort life expectancyLife expectancy decreasesPerioperative complicationsCohort studyComorbid conditionsLung parenchymaLobectomyCox modelReasonable optionPatientsNSCLCLocal control
2017
Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease
Ermer T, Kopp C, Asplin JR, Granja I, Perazella MA, Reichel M, Nolin TD, Eckardt KU, Aronson PS, Finkelstein FO, Knauf F. Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal Disease. Kidney International Reports 2017, 2: 1050-1058. PMID: 29270514, PMCID: PMC5733827, DOI: 10.1016/j.ekir.2017.06.002.Peer-Reviewed Original ResearchEnd-stage renal diseasePlasma oxalate concentrationRenal diseaseCalcium oxalate supersaturationPlasma of patientsTraditional therapeutic regimensExtended treatment timeTherapeutic regimensExtended hemodialysisUremic toxin removalHemodialysisTherapeutic strategiesTreatment sessionsPatientsBaseline pDialysis equipmentHemodialfiltrationWeeksTreatment timeOxalate concentrationRespective treatmentsDiseasePrevious reportsTreatment modeHours